2025-08-29 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co (LLY) based on the provided data.

**Report: Eli Lilly and Co (LLY) Analysis**

**0. Summary of Key Figures**

*   **Cumulative Return (LLY):** 221.41%
*   **Cumulative Return (VOO - S&P 500):** 102.60%
*   **Relative Divergence:** Current: 679.0, Relative: 62.7
*   **Current Price:** $731.96
*   **MRI:** 0.3266 (Low Risk)
*   **RSI:** 84.63 (Overbought)
*   **Expected Return:** 362.1% (vs. S&P 500, Long-Term)

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Eli Lilly and Co is a global pharmaceutical company that develops and markets medicines.
*   **Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period. The cumulative return difference is substantial (221.41% vs 102.60%). The divergence of 679.0 with a relative divergence of 62.7 indicates LLY's performance is in the upper half of its historical outperformance range compared to VOO.

**Alpha, Beta Analysis:**

| Year      | CAGR  | MDD   | Alpha | Beta | Cap(B) |
| :---------- | :---- | :---- | :---- | :--- | :----- |
| 2015-2017 | 10.0% | 56.3% | -19.0% | 0.0  | 75.7   |
| 2016-2018 | 39.0% | 58.6% | 21.0%  | -0.1 | 103.7  |
| 2017-2019 | 50.0% | 58.6% | 20.0%  | 0.3  | 117.8  |
| 2018-2020 | 52.0% | 58.6% | 33.0%  | 0.1  | 151.4  |
| 2019-2021 | 106.0% | 60.6% | 57.0%  | 0.2  | 247.6  |
| 2020-2022 | 98.0%  | 64.8% | 96.0%  | 0.2  | 328.0  |
| 2021-2023 | 133.0% | 64.8% | 115.0% | 0.3  | 522.6  |
| 2022-2024 | 150.0% | 72.2% | 124.0% | 0.2  | 692.1  |
| 2023-2025 | 74.0%  | 76.8% | 20.0%  | 0.2  | 656.2  |

*   **CAGR:** Compound Annual Growth Rate; shows the average annual growth rate over the period. The CAGR has been strong in recent years.
*   **MDD:** Maximum Drawdown; measures the largest peak-to-trough decline during the period. The MDD has been relatively high, indicating significant price volatility.
*   **Alpha:** A measure of excess return compared to the benchmark (S&P 500). Recent Alpha figures are very high, indicating substantial outperformance.
*   **Beta:** Measures the stock's volatility relative to the market. The Beta values are generally low, suggesting LLY is less volatile than the S&P 500.
*   **Cap(B):** Market Capitalization in Billions.

**2. Recent Price Action**

*   **Current Price:** $731.96
*   **Last Market Change:** Price decreased by -0.3 from previous close
*   **5-Day Moving Average:** 721.83
*   **20-Day Moving Average:** 702.83
*   **60-Day Moving Average:** 756.58

*   **Analysis:** The current price is above the 5-day and 20-day moving averages but below the 60-day moving average. This suggests recent upward momentum, but it might be facing some resistance. The slight price decrease in the last market indicates a minor pullback.

**3. Risk and Momentum Indicators**

*   **Market Risk Indicator (MRI):** 0.3266 (Low Risk) - Indicates a relatively stable market environment for LLY.
*   **RSI:** 84.63 (Overbought) - Suggests the stock may be overbought and could be due for a correction.
*   **PPO:** 1.15 - Positive, indicating upward momentum.
*   **Hybrid Signal:** Buy 90% - A strong buy signal based on the indicators.
*   **Delta_Previous_Relative_Divergence:** -0.4 (Negative) - Indicates a short-term decrease in relative performance compared to the benchmark.
*   **Expected Return:** 362.1% - High expected return suggests significant potential for long-term outperformance.
*   **Price Change Note:** The price decrease of -0.3 from the previous close is not substantial enough to indicate a major volatility event, but it should be noted in conjunction with the other indicators.

**4. Recent News & Significant Events**

*   **News Summary:** Recent news indicates that LLY has been active in terms of business developments, regulatory changes, and market events. Analysts are discussing LLY's performance, and the stock has shown some volatility. Investors are advised to monitor news and company announcements.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출         |
| :--------- | :---- | :----------- |
| 2025-08-07 | 6.3   | 15.56 B$     |
| 2025-05-01 | 3.07  | 12.73 B$     |
| 2024-10-30 | 1.08  | 11.44 B$     |
| 2024-08-08 | 3.29  | 11.30 B$     |
| 2025-08-07 | 3.29  | 11.30 B$     |

*   **Analysis:** The most recent EPS of 6.3 is significantly higher than previous quarters. Revenue has also been increasing, indicating strong growth.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :-------------- |
| 2025-06-30 | $15.56B    | 84.27%          |
| 2025-03-31 | $12.73B    | 82.53%          |
| 2024-12-31 | $13.53B    | 82.24%          |
| 2024-09-30 | $11.44B    | 81.02%          |
| 2024-06-30 | $11.30B    | 80.80%          |

**Capital and Profitability:**

| Quarter    | Equity     | ROE      |
| :--------- | :--------- | :------- |
| 2025-06-30 | $18.27B    | 30.98%   |
| 2025-03-31 | $15.76B    | 17.50%   |
| 2024-12-31 | $14.19B    | 31.07%   |
| 2024-09-30 | $14.24B    | 6.81%    |
| 2024-06-30 | $13.56B    | 21.88%   |

*   **Analysis:** Both revenue and profit margins have been increasing, showing strong financial performance. The Return on Equity (ROE) also indicates efficient use of equity to generate profits.

**7. Overall Analysis**

Eli Lilly and Co (LLY) exhibits strong financial performance and has significantly outperformed the S&P 500. Recent earnings and revenue growth are impressive, and profit margins are high. The stock is currently in overbought territory according to the RSI, suggesting a potential pullback. However, the low MRI and strong Hybrid Signal indicate a generally positive outlook. Recent news suggests ongoing business activities and market attention. The high expected return makes LLY an attractive long-term investment. While the stock exhibits low market risk, the high MDD indicates a potential short term price volatility in the future.
